Atlas Trials

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Clinical trial NCT03701334 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03701334
Sponsor
Novartis Pharmaceuticals
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Early Breast Cancer
Start date
2018-12-07
Primary completion
2030-05-29
Enrollment
5101

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.